Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Enhancing anti-inflammatory butyrate production in the gut through the reintroduction of Muribaculaceae.

EF 2024-25

Résumé
The human gut microbiota is comprised of a large number of bacteria, fungi, and viral species that collectively play a role in the host immune health, defence against disease, and digestion. Our increasingly industrialised lifestyles have resulted in corresponding changes to this microbiome, including species loss. Muribaculaceae (MB) is one such vanishing microbe, whose loss has been shown in preliminary work by our lab to reduce the growth of beneficial gut commensal bacteria that produce butyrate. Butyrate is an anti-inflammatory compound that helps maintain healthy immune system responses. We postulate that the reintroduction of MB into humans missing them may positively impact immune system function and mitigate gut inflammation. My project seeks to investigate i) how MB promotes butyrate production, and ii) evaluate its potential as a probiotic in humans. I hypothesise that that MB metabolites support the growth of butyrate producers, and that re-introduction produces a high-butyrate anti-inflammatory gut environment. First, I will identify the mechanisms through which MB induces butyrate production by exploring cooperative growth dynamics between MB and butyrate-producing species. I will analyse metabolite production and consumption to observe what aspects of MB metabolism allow this relationship. These experiments will then be repeated in mice to confirm that the observed interactions are relevant in living model organisms.Second, I will identify the conditions required for MB to serve as a probiotic treatment to reduce human gut inflammation. I will characterise the growth of human bacterial isolates of MB and work with Melius Microbiomics, a microbiota GMP company, to develop production of the probiotic and test its inoculation in mice.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530323
Name
Porter Imogen
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing anti-inflammatory butyrate production in the gut through the reintroduction of Muribaculaceae.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacteria; Immunomodulation; Microbiome
Abstract
The human gut microbiota is comprised of a large number of bacteria, fungi, and viral species that collectively play a role in the host immune health, defence against disease, and digestion. Our increasingly industrialised lifestyles have resulted in corresponding changes to this microbiome, including species loss. Muribaculaceae (MB) is one such vanishing microbe, whose loss has been shown in preliminary work by our lab to reduce the growth of beneficial gut commensal bacteria that produce butyrate. Butyrate is an anti-inflammatory compound that helps maintain healthy immune system responses. We postulate that the reintroduction of MB into humans missing them may positively impact immune system function and mitigate gut inflammation. My project seeks to investigate i) how MB promotes butyrate production, and ii) evaluate its potential as a probiotic in humans. I hypothesise that that MB metabolites support the growth of butyrate producers, and that re-introduction produces a high-butyrate anti-inflammatory gut environment. First, I will identify the mechanisms through which MB induces butyrate production by exploring cooperative growth dynamics between MB and butyrate-producing species. I will analyse metabolite production and consumption to observe what aspects of MB metabolism allow this relationship. These experiments will then be repeated in mice to confirm that the observed interactions are relevant in living model organisms.Second, I will identify the conditions required for MB to serve as a probiotic treatment to reduce human gut inflammation. I will characterise the growth of human bacterial isolates of MB and work with Melius Microbiomics, a microbiota GMP company, to develop production of the probiotic and test its inoculation in mice.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Porter, Imogen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~